Form 4: Pieris Pharmaceuticals COO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Kathleen Goin, Chief Operating Officer of Pieris Pharmaceuticals, Inc., sold 4,302 shares of common stock on September 16, 2026.

Summary

  • Option exercise/conversion: acquired 2,154 Common Stock at $7.14 ($15,380) on September 16, 2026; holds 2,154 after (Direct).
  • Option exercise/conversion: acquired 2,148 Common Stock at $9.08 ($19,504) on September 16, 2026; holds 4,302 after (Direct).
  • Open-market sale: disposed of 1,659 Common Stock at $151.16 ($250,773) on September 16, 2026; holds 2,643 after (Direct).
  • Open-market sale: disposed of 989 Common Stock at $152.36 ($150,686) on September 16, 2026; holds 1,654 after (Direct).
  • Open-market sale: disposed of 1,654 Common Stock at $153.24 ($253,465) on September 16, 2026 (Direct).
  • Option exercise/conversion: disposed of 2,154 Stock Option (Right to Buy) on September 16, 2026; holds 2,165 after (Direct).
  • Option exercise/conversion: disposed of 2,148 Stock Option (Right to Buy) on September 16, 2026; holds 2,148 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $654,923 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Kathleen Goin — Officer (Chief Operating Officer)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-16Option exercise/conversionCommon Stock2,154$7$15.4K2,154
2026-09-16Option exercise/conversionCommon Stock2,148$9$19.5K4,302
2026-09-16Open-market saleCommon Stock1,659$151$250.8K2,643
2026-09-16Open-market saleCommon Stock989$152$150.7K1,654
2026-09-16Open-market saleCommon Stock1,654$153$253.5K0
2026-09-16Option exercise/conversionStock Option (Right to Buy)2,154——2,165
2026-09-16Option exercise/conversionStock Option (Right to Buy)2,148——2,148

Key Dates

DateDescription
2026-09-16Option exercise/conversion (2,154 shares)
2026-09-16Option exercise/conversion (2,148 shares)
2026-09-16Open-market sale (1,659 shares)
2026-09-16Open-market sale (989 shares)
2026-09-16Open-market sale (1,654 shares)
2026-09-16Option exercise/conversion (2,154 shares)
2026-09-16Option exercise/conversion (2,148 shares)

Keywords

insider transaction, Form 4, PVLA, PALVELLA THERAPEUTICS, INC., bearish, Kathleen Goin

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.